Role of NGAL in Vitiligo
Role of Serum NGAL Inearly Detection of CVR in Patients With Vitiligo
1 other identifier
interventional
90
1 country
1
Brief Summary
Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 7, 2021
CompletedFirst Posted
Study publicly available on registry
March 22, 2022
CompletedStudy Start
First participant enrolled
December 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2022
CompletedOctober 31, 2022
December 1, 2021
Same day
November 7, 2021
October 28, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
serum Neutrophil Gelatinase-associated Lipocalin in patients with Vitilig
Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo
6 months
Study Arms (2)
Cases
ACTIVE COMPARATORgroup of vitiligo patients
control group
ACTIVE COMPARATORhealthy group
Interventions
Eligibility Criteria
You may qualify if:
- patients with vitiligo above 20y
You may not qualify if:
- patients with systemic disease Pregnants female Lactating females Patients less than 20 y Patients with active lesions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag fuculty
Sohag, Egypt
Related Publications (4)
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15.
PMID: 25596811BACKGROUNDVachiramon V, Onprasert W, Harnchoowong S, Chanprapaph K. Prevalence and Clinical Characteristics of Itch in Vitiligo and Its Clinical Significance. Biomed Res Int. 2017;2017:5617838. doi: 10.1155/2017/5617838. Epub 2017 Jul 30.
PMID: 28828385BACKGROUNDSilverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013 Feb;149(2):159-64. doi: 10.1001/jamadermatol.2013.927.
PMID: 23560296BACKGROUNDMazzei Weiss ME. Vitiligo: to biopsy or not to biopsy? Cutis. 2020 Apr;105(4):189-190. No abstract available.
PMID: 32463851BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Marwa M Abd El-Meged, professor
CONTACT
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- resident doctor at dermatology department sohag university hospital
Study Record Dates
First Submitted
November 7, 2021
First Posted
March 22, 2022
Study Start
December 15, 2022
Primary Completion
December 15, 2022
Study Completion
December 15, 2022
Last Updated
October 31, 2022
Record last verified: 2021-12